Avalon Investment & Advisory’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | $39.7M | Sell |
248,957
-5,233
| -2% | -$800K | 1.09% | 30 |
|
|
2022
Q4 | $41.1M | Sell |
254,190
-2,333
| -0.9% | -$358K | 1.17% | 26 |
|
|
2022
Q3 | $34.4M | Sell |
256,523
-192,533
| -43% | -$27.6M | 1.07% | 33 |
|
|
2022
Q2 | $68.8M | Sell |
449,056
-141,854
| -24% | -$21.7M | 1.94% | 5 |
|
|
2022
Q1 | $95.8M | Sell |
590,910
-31,895
| -5% | -$4.63M | 2.31% | 4 |
|
|
2021
Q4 | $84.3M | Sell |
622,805
-89,477
| -13% | -$10.6M | 2.08% | 5 |
|
|
2021
Q3 | $76.8M | Sell |
712,282
-36,296
| -5% | -$4.15M | 1.78% | 10 |
|
|
2021
Q2 | $84.3M | Sell |
748,578
-74,058
| -9% | -$8.34M | 1.87% | 9 |
|
|
2021
Q1 | $89M | Sell |
822,636
-225,920
| -22% | -$24.2M | 2.04% | 7 |
|
|
2020
Q4 | $112M | Buy |
1,048,556
+12,550
| +1% | +$1.21M | 2.29% | 6 |
|
|
2020
Q3 | $90.7M | Sell |
1,036,006
-21
| -0% | -$1.98K | 2.02% | 9 |
|
|
2020
Q2 | $102M | Buy |
1,036,027
+87,077
| +9% | +$7.67M | 2.35% | 6 |
|
|
2020
Q1 | $72.3M | Buy |
948,950
+422,484
| +80% | +$36M | 1.85% | 9 |
|
|
2019
Q4 | $46.6M | Buy |
526,466
+37,833
| +8% | +$3.14M | 0.95% | 26 |
|
|
2019
Q3 | $37M | Buy |
488,633
+253,759
| +108% | +$17.4M | 0.82% | 31 |
|
|
2019
Q2 | $17.1M | Sell |
234,874
-1,745
| -0.7% | -$137K | 0.38% | 88 |
|
|
2019
Q1 | $19.1M | Sell |
236,619
-168,540
| -42% | -$13.8M | 0.43% | 73 |
|
|
2018
Q4 | $37.4M | Buy |
405,159
+221,819
| +121% | +$19.5M | 0.96% | 24 |
|
|
2018
Q3 | $17.3M | Sell |
183,340
-183,331
| -50% | -$17.4M | 0.49% | 67 |
|
|
2018
Q2 | $34M | Sell |
366,671
-13,257
| -3% | -$1.29M | 1.01% | 21 |
|
|
2018
Q1 | $36M | Buy |
379,928
+61,700
| +19% | +$6.78M | 1.11% | 20 |
|
|
2017
Q4 | $30.8M | Sell |
318,228
-22,426
| -7% | -$2.11M | 0.96% | 27 |
|
|
2017
Q3 | $30.3M | Buy |
340,654
+1,047
| +0.3% | +$79.7K | 0.96% | 26 |
|
|
2017
Q2 | $24.6M | Sell |
339,607
-3,034
| -0.9% | -$204K | 0.82% | 34 |
|
|
2017
Q1 | $22.3M | Sell |
342,641
-90,932
| -21% | -$5.72M | 0.77% | 41 |
|
|
2016
Q4 | $27.1M | Sell |
433,573
-10,747
| -2% | -$656K | 0.98% | 30 |
|
|
2016
Q3 | $28M | Sell |
444,320
-238
| -0.1% | -$15.4K | 1.05% | 28 |
|
|
2016
Q2 | $27.5M | Buy |
444,558
+229,209
| +106% | +$14M | 1.06% | 30 |
|
|
2016
Q1 | $12.3M | Buy |
215,349
+4,026
| +2% | +$224K | 0.53% | 78 |
|
|
2015
Q4 | $12.5M | Sell |
211,323
-2,878
| -1% | -$166K | 0.54% | 77 |
|
|
2015
Q3 | $11.7M | Buy |
214,201
+719
| +0.3% | +$46.8K | 0.51% | 83 |
|
|
2015
Q2 | $14.3M | Sell |
213,482
-643
| -0.3% | -$42K | 0.62% | 64 |
|
|
2015
Q1 | $12.5M | Sell |
214,125
-174,821
| -45% | -$10.6M | 0.55% | 86 |
|
|
2014
Q4 | $25.5M | Buy |
388,946
+19,229
| +5% | +$1.21M | 1.16% | 26 |
|
|
2014
Q3 | $21.4M | Buy |
369,717
+2,631
| +0.7% | +$146K | 1.08% | 25 |
|
|
2014
Q2 | $20.7M | Buy |
367,086
+2,098
| +0.6% | +$110K | 1.05% | 26 |
|
|
2014
Q1 | $18.8M | Sell |
364,988
-17,620
| -5% | -$891K | 1.04% | 26 |
|
|
2013
Q4 | $20.2M | Buy |
382,608
+8,299
| +2% | +$408K | 1.13% | 22 |
|
|
2013
Q3 | $16.7M | Sell |
374,309
-15,838
| -4% | -$702K | 1.08% | 25 |
|
|
2013
Q2 | $16.1M | Buy |
+390,147
| New | +$17.1M | 0.96% | 29 |
|
Other funds holding ABBV
Avalon Investment & Advisory's ABBV Position: Q1 2023 in Review
Avalon Investment & Advisory reduced its AbbVie (ABBV) stake by 2.1% in Q1 2023, selling an estimated $800K and leaving 248,957 shares worth $39.7M. The position accounts for 1.09% of the portfolio, ranked #30.
Avalon Investment & Advisory first reported a position in ABBV in Q2 2013 and has held it in 40 quarters since. The position peaked at $112M in Q4 2020. 3,138 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.
- Avalon Investment & Advisory held 248,957 shares of AbbVie worth $39.7M as of Q1 2023.
- Avalon Investment & Advisory sold 5,233 AbbVie shares in Q1 2023, an estimated $800K.
- AbbVie made up 1.09% of Avalon Investment & Advisory's portfolio in Q1 2023, its #30 holding.
- Avalon Investment & Advisory first reported a position in AbbVie in Q2 2013 and has held it in 40 quarters since.
- Avalon Investment & Advisory's AbbVie position peaked at $112M in Q4 2020.
- 3,138 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.
Based on Avalon Investment & Advisory's 13F filing for Q1 2023, filed 15 May 2023.